New strategies in the treatment of acute myelogenous leukemia (AML): In vitro culture of AML cells - The present use in experimental studies and the possible importance for future therapeutic approaches

Stem Cells

Volumn 19, Issue 1, 2001, Pages 1-11

  Bruserud, Øystein ^a   Gjertsen, Bjørn Tore ^a   Foss, Brynjar ^a   Huang, Tien Sheng ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myelogenous leukemia; Apoptosis; Chemotherapy; Experimental models; In vitro culture

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CANCER CHEMOTHERAPY; CELL CULTURE; CELL LINE; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; LABORATORY TEST; PROGNOSIS; REVIEW; RISK ASSESSMENT; STEM CELL; TREATMENT PLANNING; XENOTRANSPLANTATION;

EID: 0035176551     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.19-1-1     Document Type: Review

References (75)

1. New strategies in the treatment of acute myelogenous leukemia: Differentiation induction - Present use and future possibilities
2. Acute myeloid leukemia
3. Acute promyelocytic leukemia: A curable disease
4. Clinical significance of cytogenetics in acute myeloid leukemia
5. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: Possible implications for future therapeutic strategies
6. New strategies in the treatment of acute myelogenous leukemia: Mobilization and transplantation of autologous stem cells in adult patients
7. In vitro growth in acute myeloid leukemia: Clinico-biological correlations
8. In vitro growth in acute myelogenous leukaemia: Relationship with other clinico-biological characteristics of the disease
9. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia
10. Relation of blast cell survival and proliferation to chemotherapy resistance in AML
11. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia
12. Prognostic significance of the blast self-renewal capacity in patients with acute myeloid leukemia
13. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory comittee meeting - Airlie House, Virginia, November 1997
14. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission
15. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GINEMA AML 8A trial
16. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities
17. Differential expression of adhesion molecules in acute leukemia
18. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia
19. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo
20. + cell enrichment by magnetic field, magnetic beads or chromatography separation
21. Effects of interferon (IFN) alpha on the expression of interleukin 1 beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and minor necrosis factor alpha (TNF) in acute myeloid leukemia blasts
22. Mechanisms of growth factor expression in acute myeloid leukemia (AML)
23. Induction of death (CD95/Fas), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma
24. CD54 expression and its role in homotypic aggregation of the blasts of acute myeloblastic leukemia
25. Effects of normal platelets on proliferation and constitutive cytokine secretion by human acute myelogenous leukemia blasts
26. Effects of acute myelogenous leukemia blasts on platelet release of soluble P-selectin and platelet-derived growth factor
27. Autologous stem cell transplantation as postremission therapy in adult acute myelogenous leukemia; does the platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse
28. Guidelines for the characterization and publication of human malignant hematopoietic cell lines
29. History and classification of human leukemia-lymphoma cell lines
30. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
31. Effects of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells
32. In vitro culture of acute myelogenous leukemia blasts: A comparison of four different culture media
33. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media; studies of native AML blasts and AML cell lines
34. Dynamics of interaction between DNA-specific antitumor agents and serum-contained cytokines in the initiation of ML-1 human myeloblastic leukemia cell differentiation
35. Human AML colony growth in serum-free culture
36. Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids
37. Effects of n-3 and n-6 fatty acids on proliferation and differentiation of promyelocytic leukemic HL-60 cells
38. Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia
39. Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF α- and β-receptor signals in cells expressing both receptor types
40. Interleukin 9 stimulates proliferation of human myeloid leukemic cells
41. In vitron effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts
42. -/HLA-DR-Blood
43. Programmed cell death regulation: Basic mechanisms and therapeutic opportunities
44. BCL-XL is heterogeneously expressed by acute myeloblastic leukemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression
45. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes
46. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
47. Apoptosis detection: An overview
48. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line
49. Phosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression
50. Biochemical pathways of caspase activation during apoptosis
51. Two distinct pathways leading to nuclear apoptosis
52. Transient inhibition of histone deacetylase activity overcomes silencing in the mating region in fission yeast
53. Transcriptional control of adrenomedullin induction by phorbol ester in human monocytic leukemia cells
54. Iron metabolism
55. Apoptosis induced by hydrogen peroxide under serum deprivation and its inhibition by antisense c-jun in F-MEL cells
56. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
57. The proliferation in suspension Of the progenitors of the blast cells in acute myeloblastic leukemia
58. Growth regulation of human acute myeloid leukemia: Effects of five recombinant hematopoietic factors in a serum-free culture system
59. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells
60. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture
61. Human stem cell assays in immunodeficient mice
62. A cell initiating acute myeloid leukemia after transplantation into SCID mice
63. Bcl-2 expression in acute myeloblastic leukemia: Relationship with autonomous growth and CD34 antigen expression
64. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor
65. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells
66. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics
67. Caspase 2 and 3 protein levels are predictors of survival in acute myelogenous leukemia
68. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemia relapse
69. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T cell responses
70. Human acute myelogenous leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias
71. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model
72. In vitro autonomous proliferation in AML: Clinical and biological significance
73. Diagnostic and prognostic significance of the CFU-C assay in acute nonlymphoblastic leukemia
74. Effects of γ-irradiation on acute myelogenous leukemia blasts: In vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation
75. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels